São Paulo’s Butantan Biological Institute announced it will begin production of its very own coronavirus vaccine, ButanVac. However, the institute still lacks regulatory approval to hold clinical trials on the immunizer. Federal regulator Anvisa suspended requests due to a lack of documentation.
Governor João Doria nevertheless called it “significant news for Brazilian and global science.” Butantan expects to produce 18 million doses in 2021.
The ButanVac uses technology developed by the New York-based Mount Sinai Health System and is being developed not only in Brazil, but also in Vietnam, Thailand, and Mexico. So far, the only 100-percent Latin American vaccine in development is Cuba’s Soberana 02.